Search clinical trials for: MOR202

Total 40 results

HI-Bio

Completed

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (M-PLACE)

Glomerulonephritis, Membranous | antiPLA2R Positive

Spain, Belgium, Australia, Italy, United States, Korea, Republic of, France, Netherlands, Poland
MorphoSys AG

Terminated

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Acute Lymphoblastic Leukemia

United States
Sorriso Pharmaceuticals, Inc.

Recruiting

A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis

Ulcerative Colitis

Ukraine, Georgia
A2 Healthcare Taiwan Corporation
GoldenMed BioTechnology

Withdrawn

A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients

Hepatocellular Carcinoma | Liver Fibrosis | HEPATITIS B CHRONIC

Taiwan
Galapagos NV

Terminated

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis (GECKO)

Atopic Dermatitis

United States
Guy's and St Thomas' NHS Foundation Trust
King's College London

Recruiting

The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 (MONACO)

Covid19 | Pulmonary Fibrosis | Interstitial Lung Disease

United Kingdom
MorphoSys AG

Completed

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, Belgium, Germany, Hungary, Italy, Poland, Spain
Mario Negri Institute for Pharmacological Research
MorphoSys AG

Active, not recruiting

MOR202 for Refractory MN (MONET)

Membranous Nephropathy

Italy
Farsad Eskandary
Charite University, Berlin, Germany; University of Alberta; HI-Bio

Completed

Felzartamab in Late Antibody-Mediated Rejection

Antibody-mediated Rejection

Austria, Germany
HI-Bio

Completed

Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) (NewPLACE)

Glomerulonephritis | Membranous Nephropathy | antiPLA2R Positive

Taiwan, Korea, Republic of, Greece, Germany, United Kingdom, Georgia, Russian Federation
HI-Bio

Active, not recruiting

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)

Immunoglobulin A (IgA) Nephropathy

United Kingdom, Germany, Spain, Serbia, Taiwan, Australia, Japan, Korea, Republic of, Belgium, United States, Bulgaria, Czechia, Georgia, Malaysia, Philippines, Ukraine
Alan Richardson
Quotient Clinical

Terminated

First in Human Single Ascending Dose Study of MOR107

Safety

United Kingdom
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
Galapagos NV

Terminated

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Healthy | Atopic Dermatitis

Spain, Germany, Ukraine, United Kingdom
MorphoSys AG

Completed

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Multiple Sclerosis

Germany, Poland, United Kingdom
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Lemonex

Recruiting

Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)

COVID-19 Infection | COVID-19 Vaccine Adverse Reaction

Korea, Republic of
MorphoSys AG

Completed

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Germany, Netherlands, Poland, Ukraine
Shanghai Zerun Biotechnology Co.,Ltd

Active, not recruiting

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

COVID-19 | SARS-CoV-2 Infection

Mali
James Rubenstein
Incyte Corporation

Recruiting

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Primary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System Lymphoma

United States
OncoResponse, Inc.

Recruiting

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Cancer | Metastatic Cancer | Advanced Solid Tumor | Platinum-resistant Ovarian Cancer | Malignant Neoplasm | Tumor, Solid | Cutaneous Squamous Cell Carcinoma

United States
The Lymphoma Academic Research Organisation

Recruiting

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

DLBCL

France, Belgium
Taizhou EOC Pharma Co., Ltd.

Completed

Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

Solid Tumor, Adult

China
MorphoSys AG

Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, United Kingdom, Austria, Germany, Italy, Poland
Taizhou EOC Pharma Co., Ltd.

Not yet recruiting

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Solid Tumor, Adult
Alvogen Korea

Completed

Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers

Healthy

Korea, Republic of
Alvogen Korea

Completed

Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers

Healthy

Korea, Republic of
Alvogen Korea

Completed

Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions

Healthy

Korea, Republic of
Mundipharma Research Limited

Completed

Study to Assess Pharmacokinetic (PK), Bioavailability & Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral Solution

Opioid Substitution Treatment
Alvogen Korea

Completed

Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease (DAVICI)

Peripheral Arterial Disease
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Chronic Graft Versus Host Disease | Hematologic and Lymphocytic Disorder | Steroid Refractory Graft Versus Host Disease

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (V-MIND)

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Incyte Corporation; Ipsen; BeiGene

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
Timothy Voorhees

Recruiting

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Polymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

United States
David Bond, MD

Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
University of Washington

Recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States

Search clinical trials for: MOR202

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations